ScholarLens Back to search
2017•Evidence-Based PracticeRequires access

Which treatment is best for hepatic encephalopathy due to end-stage liver disease?

Danette Null, Jessica Langevin, Jason L. Hagen

Open publisher page 0 citations

Abstract

EVIDENCE-BASED ANSWER Rifaximin is as effective as other antibiotics or oral disaccharides for improving hepatic encephalopathy with a better safety profile (SOR: A, meta-analysis of RCTs). Combination therapy of rifaximin and lactulose is more effective for reversal of hepatic encephalopathy with less mortality than lactulose alone (SOR: B, RCT). Prophylactic use of rifaximin plus lactulose reduces hospitalizations for hepatic encephalopathy more than lactulose alone (SOR: B, RCT).

About this research paper

What this paper is about

EVIDENCE-BASED ANSWER Rifaximin is as effective as other antibiotics or oral disaccharides for improving hepatic encephalopathy with a better safety profile (SOR: A, meta-analysis of RCTs). Combination therapy of rifaximin and lactulose is more effective for reversal of hepatic encephalopathy with less mortality than lactulose alone (SOR: B, RCT). Prophylactic use of rifaximin plus lactulose reduces hospitalizations for hepatic encephalopathy more than lactulose alone (SOR: B, RCT).

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

EVIDENCE-BASED ANSWER Rifaximin is as effective as other antibiotics or oral disaccharides for improving hepatic encephalopathy with a better safety profile (SOR: A, meta-analysis of RCTs). Combination therapy of rifaximin and lactulose is more effective for reversal of hepatic encephalopathy with less mortality than lactulose alone (SOR: B, RCT). Prophylactic use of rifaximin plus lactulose reduces hospitalizations for hepatic encephalopathy more than lactulose alone (SOR: B, RCT).

Key concepts: Lactulose, Rifaximin, Hepatic encephalopathy, Medicine, Randomized controlled trial, Gastroenterology, Internal medicine, Encephalopathy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Which treatment is best for hepatic encephalopathy due to end-stage liver disease? — Research Paper | ScholarLens